

23 Mar 05
200501779-3

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

CORRECTED VERSION

(19) World Intellectual Property
Organization
International Bureau



162162

(43) International Publication Date
1 April 2004 (01.04.2004)

PCT

(10) International Publication Number
WO 2004/026844 A1

(51) International Patent Classification⁷: **C07D 251/18**,
251/70, 401/04, 407/04, 409/04, 413/10, 417/04, A61K
31/53, A61P 35/00, 19/02, 17/06

500080 (IN). **KUMAR, Potlapally, Rajender** [IN/IN];
Plot N° 22, Lake View Enclave, Miyapur, Hyderabad
500050 (IN). **REDDY, Gaddam, Om** [IN/IN]; Plot #5 &
6, Lake View Enclave, Miyapur, Hyderabad 500050 (IN).

(21) International Application Number:
PCT/US2003/009356

(74) Agent: **ARNOLD, Jeffery, B.**; Womble Carlyle Sandridge
& Rice, PLLC, P.O. Box 7037, Atlanta, GA 30357-0037
(US).

(22) International Filing Date: 26 March 2003 (26.03.2003)

(25) Filing Language: English

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD,
SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US,
UZ, VC, VN, YU, ZA, ZM, ZW.

(26) Publication Language: English

(30) Priority Data:
10/253,388 23 September 2002 (23.09.2002) US
10/390,485 17 March 2003 (17.03.2003) US

(71) Applicant (*for all designated States except US*): **REDDY
US THERAPEUTICS, INC.** [US/US]; 3065 Northwoods
Circle, Norcross, GA 30071-1542 (US).

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO,
SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM,
GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **TIMMER, Richard,
T.** [US/US]; 1729 Coventry Road, Decatur, GA 30030
(US). **ALEXANDER, Christopher, W.** [US/US]; 1981
Jordan Terrace NE, Atlanta, GA 30345 (US). **PIL-
LARISSETTI, Sivaram** [IN/US]; 4762 Grand Heron
Court, Norcross, GA 30092 (US). **SAXENA, Uday**
[IN/US]; 2900 Galahad Drive, Atlanta, GA 30345 (US).
YELESWARAPU, Koteswar, Rao [IN/IN]; Flat n°
203, Krishna Kastury Arcae, Plot n° 69 & 70, Methodist
Colony, Begumpet, Hyderabad 500016 (IN). **PAL,
Manojit** [IN/IN]; JPN Nagar, Bollaram Road, Miyapur,
Hyderabad 500049 (IN). **REDDY, Jangalgar, Tirupathy**
[IN/IN]; Flat N° 313, SMR Metropolis Apts., Miyapur,
Hyderabad 500050 (IN). **REDDY, Velagala, Venkata,
Rama, Murali, Krishna** [IN/IN]; EWS 1288, KPHB
Colony, Kukatpally, Hyderabad 500072 (IN). **SRIDEVI,
Bhatlapenumarthy, Sesha** [IN/IN]; 1-1-508/1, B 102,
Balaji Indraprastha Apts., Grandhinagar, Hyderabad

Published:

— with international search report

(48) Date of publication of this corrected version:

11 November 2004

(15) Information about Correction:

see PCT Gazette No. 46/2004 of 11 November 2004, Sec-
tion II

*For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.*

(54) Title: METHODS AND COMPOSITIONS OF NOVEL TRIAZINE COMPOUNDS

(57) Abstract: The present invention relates to methods and compositions comprising compounds that treat pathophysiological conditions arising from inflammatory responses. In particular, the present invention is directed to compounds that inhibit or block glycated protein produced induction of the signaling-associated inflammatory response in endothelial cells. The present invention relates to compounds that inhibit smooth muscle proliferation. In particular, the present invention is directed to compounds that inhibit smooth muscle cell proliferation by modulating HSPGs such as Perlecan. The present invention further relates to the use of compounds to treat vascular occlusive conditions characterized by smooth muscle proliferation such as restenosis and atherosclerosis.

WO 2004/026844 A1



ACTION